Bausch & Lomb drops after ending sales process
Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch ...
Yahoo Finance6d
Bausch + Lomb Sale Stumble Frustrates Bausch Health Investors
Bausch Health Companies Inc.’s years-long process of trying to separate its Bausch + Lomb Corp. eye-care business hit a roadblock Thursday when a potential sale to private equity fell through ...
MassDevice6d
Bausch + Lomb won’t sell after engaging with potential buyers
Bausch + Lomb announced today that, after engagement with potential buyers, it has no immediate plan to sell. At the end of 2024, the company issued a statement outlining its plans for a potential ...
Contact Lens Maker Bausch + Lomb Rules Out Going Private at This Time
(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday, sending its ...
Bausch + Lomb Corporation Stock Drops 8% After Privatization Effort Ends
Bausch + Lomb Corporation (BLCO) is down by 8.45 percent during Thursday's trading, falling $1.56 to $16.19. The stock dropped after ...
Healio28d
Character Biosciences, Bausch + Lomb to collaborate on development of AMD treatments
The collaboration may expand into other ocular conditions. Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age ...
Bausch Health board determines not to move forward with Bausch + Lomb sale
Bausch Health Companies (BHC) issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (BLCO), which was ...
Business Wire1mon
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an ...